Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Sigyn Therapeutics Inc SIGY

Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:RE:Great new firm

In a head-to-head comparison with the leading endotoxin adsorber, Toraymyxin™ (Toray, Japan), CytoSorb-XL matched the level of endotoxin reduction in an in vitro plasma more

Sigyn has developed a device

The primary cause of death during the COVID-19 pandemic has been a cytokine storm. Sigyn Therapeutics Inc. has developed a device to prevent this. This device has the potential to target more

Who is FormTex?

Newly acquired by Good Natured for USD $4.8M, FormTex generated unaudited revenue of USD $5.1M for the trailing twelve months ended February 28, 2022, and an unaudited gross margin rate of approximately 42% in FY2021. Through this acquisition, GDNP now has strategic access to Texas and the Southern US. and will be able to leverage Houston-based manufacturing, importing, warehousing, and logistics to service the southeastern U.S. market, including Florida, Georgia, and North Carolina. more

RE:Great new firm

testing ; - ) SouthernTierTom (1245) User Actions   March 29, 2021 - 12:04 AM 162 Reads Post# 32896467 more